[Latest] Global Aesthetics Injectables Market Size/Share Worth USD 35,976.2 Million by 2033 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
13 août 2024 00h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Aesthetics Injectables Market Size, Trends and Insights By Product Type...
EPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the Firm
01 juil. 2022 00h03 HE
|
Bragar Eagel & Squire
NEW YORK, July 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme
17 déc. 2021 01h00 HE
|
GENFIT S.A.
GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long...
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
17 déc. 2021 01h00 HE
|
GENFIT S.A.
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership ...